Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
Become a Member | Sign in
Home>News>This Article

Do you Want to Make the Move from Diagnostics to BiognostiX?

Published: Thursday, February 20, 2014
Last Updated: Thursday, February 20, 2014
Bookmark and Share
Symposium ‘Leading the way from diagnostics to BiognostiX’ to be held on 27 February 2014 in UK.

A symposium focusing on the results of a 3-year EU-funded programme to design a novel fibre-based microfluidic technology to enables rapid and simple point-of-use diagnostic testing will be held at the Hauser Forum, Cambridge, UK, on 27 February 2014.

The BiognostiX™ consortium, headed by experts at FFEI Life Science, has brought together academic, research and commercial partners from five European countries, and now the symposium ‘Leading the way from diagnostics to BiognostiX’, will feature presentations from each, accelerating the process of disseminating the proof of principle data generated as part of the project.

George Hutchinson, Director, FFEI Life Science, said, “We are at a very exciting stage in the development of the programme and we are keen to meet new partners who have a need for the BiognostiX technology. Rapid, low cost, multiplex diagnostic testing on this simple device is an appealing option for a wide range of applications, in veterinary, agri-food and human diagnostic, for example.”

The desired assay biochemistry, microfluidics and a novel particle technology platform are combined on a BiognostiX Chip™. Composed of a fibre-based substrate, each BiognostiX Chip is mechanically treated to create a microfluidic channel pattern.

Reagents are deposited using fluid-jet technologies to deliver picolitre quantities of capture complex - Immuno-Ink™ - into specific zones of the channels.

The simplicity and flexibility of the manufacturing process allows for changes in chip configuration during the assay development process.

The number of microfluidic channels can be varied depending on assay requirements and the residence time of the sample can be adjusted to control the interaction time between the sample and the Immuno-Ink.

The output of the immunoassays can be quantified using densiometric, colorimetric or fluorometric techniques. Once the biochemistry and chip are optimized, they are then fixed for simple, low-cost manufacture.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

BiognostiX Symposium Draws a Crowd to Hauser Forum
Company to share the results of this 3-year EU funded FP7 research programme.
Thursday, May 15, 2014
Scientific News
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Biomedical Imaging at One-Thousandth the Cost
Mathematical modeling enables $100 depth sensor to approximate the measurements of a $100,000 piece of lab equipment.
Improving Outcomes for Lung Cancer and Diabetic Patients
Novel technologies have been developed with support from SBRI Healthcare funding.
New Way of Detecting Cancer
A new RNA test of blood platelets can be used to detect, classify and pinpoint the location of cancer by analysing a sample equivalent to one drop of blood.
Rapid, Portable Ebola Diagnostic
Scientists confirmed the efficiency of the novel Ebola detection method in field trials.
New, Better Test for Prostate Cancer
A study from Karolinska Institutet shows that a new test for prostate cancer is better at detecting aggressive cancer than PSA.
Blood Test Picks Out Prostate Cancer Drug Resistance
Scientists have developed a blood test that can identify key mutations driving resistance to a widely used prostate cancer drug, and identify in advance patients who will not respond to treatment.
Antibody Targets Key Cancer Marker
University of Wisconsin-Madison researchers have created a molecular structure that attaches to a molecule on highly aggressive brain cancer and causes tumors to light up in a scanning machine.
Key Piece of MRSA Vaccine Puzzle
New research funded by the Health Research Board and the Wellcome Trust has pinpointed immune cells that could be targeted by an MRSA vaccine.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos